SCHEMBL20913835

SCHEMBL20913835

CC(C)(C)OC(=O)N1CCC(F)(F)C(CC(=O)O)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
USP30 Q70CQ3 1/20 0.37
HPGD P15428 1/20 0.37
GPR119 Q8TDV5 3/20 0.36
EPHX2 P34913 1/20 0.36
TACR1 P25103 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25339655 0.87 NR1H2 (0.41) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL2348311 0.86 NR1H2 (0.49) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL28569492 0.86 NR1H2 (0.42) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL2349633 0.84 NR1H2 (0.41) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL19448428 0.83 NR1H2 (0.43) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL29831252 0.83 NR1H2 (0.43) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL31470261 0.82 USP30 (0.41) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL31616165 0.82 NAMPT (0.40) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL20913884 0.82 NR1H2 (0.40) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL19456384 0.81 GPR119 (0.41) NR1H2MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528826-B2 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-01-20 US disclosed
US-20240217987-A1 INHIBITOR COMPOUNDS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-07-04 US disclosed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
EP-3440069-B1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-10-28 EP disclosed
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2020-03-10 US disclosed
EP-3440075-B1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-01-29 EP disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528826-B2 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors BCL6, BCL6B, BCL3 NR1H2 689/4885MEN1 2818/4885ALDH1A1 1668/4885
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT NR1H2 251/4885MEN1 3573/4885ALDH1A1 2114/4885
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors BRD4, BRD3, BRD2 NR1H2 503/4885MEN1 2810/4885ALDH1A1 1158/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT NR1H2 251/4885MEN1 3573/4885ALDH1A1 2114/4885
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 NR1H2 503/4885MEN1 2810/4885ALDH1A1 1158/4885
US-20240217987-A1 INHIBITOR COMPOUNDS BCL6, BCL6B, BCL3 NR1H2 1082/4885MEN1 1032/4885ALDH1A1 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.